With the increasing diabetic population worldwide, diabetic foot ulcers (DFUs) are a significant concern. This study aimed to compare the efficacy of skin substitutes, biomaterials, and topical agents with standard care.
Recent Advances:
A meta-analysis was conducted using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, EMBASE, and Web of Science were searched using the following keywords: diabetes mellitus AND skin graft OR tissue replacement OR dressing OR drug. Two independent reviewers performed data collection and quality assessment of the eligible studies. The primary outcome was the 12- to 16-week healing rates and the secondary outcome was recurrence rates.
Critical Issues:
Thirty-eight randomized controlled trials, including 3,862 patients, were analyzed. The studies exhibited low heterogeneity (τ2 = 0.10) without significant asymmetry (Egger's test, p = 0.8852). After pooling direct and indirect estimates, placenta-based tissue products exhibited the best wound healing probability (p-score = 0.90), followed by skin substitutes with living cells (p-score = 0.70), acellular skin substitutes (p-score = 0.56), and advanced topical dressings (p-score = 0.34) compared with standard of care. The recurrence analysis showed significant improvement in the intervention group compared with the control group (11.21% vs. 15.15%).
Future Directions:
This network meta-analysis provides the relative effectiveness and rank of biomaterials and topical dressings in DFU healing. The results could help clinical decision making.
ArmstrongDG, BoultonAJM, BusSA. Diabetic foot ulcers and their recurrence. N Engl J Med, 2017; 376(24):2367–2375; doi: 10.1056/NEJMra1615439
3.
ZhangP, LuJ, JingY, et al.Global epidemiology of diabetic foot ulceration: A systematic review and meta-analysis. Ann Med, 2017; 49(2):106–116; doi: 10.1080/07853890.2016.1231932
4.
International Diabetes Federation. IDF Diabetes Atlas, 10th ed. International Diabetes Federation: Brussels, Belgium; 2021.
5.
ClaxtonMJ, ArmstrongDG, BoultonAJM. Healing the diabetic wound and keeping it healed: Modalities for the early 21st century. Curr Diab Rep, 2002; 2(6):510–518; doi: 10.1007/s11892-002-0121-3
6.
SantemaTB, PoyckPP, UbbinkDT. Skin grafting and tissue replacement for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev, 2016; 2017:3; doi: 10.1002/14651858.cd011255.pub2
7.
GordonAJ, AlfonsoAR, NicholsonJ, et al.Evidence for healing diabetic foot ulcers with biologic skin substitutes: A systematic review and meta-analysis. Ann Plast Surg, 2019; 83(4 Suppl 1):S31–S44; doi: 10.1097/sap.0000000000002096
8.
McGuinnessLA, HigginsJPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods, 2021; 12(1):55–61; doi: 10.1002/jrsm.1411
RückerG, SchwarzerG. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol, 2015; 15(1):58; doi: 10.1186/s12874-015-0060-8
11.
VevesA, SheehanP, PhamHT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg, 2002; 137(7):822–827; doi: 10.1001/archsurg.137.7.822
12.
TomWL, PengDH, AllaeiA, et al.The effect of short-contact topical tretinoin therapy for foot ulcers in patients with diabetes. Arch Dermatol, 2005; 141(11):1373–1377; doi: 10.1001/archderm.141.11.1373
13.
DriverVR, HanftJ, FyllingCP, et al.A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage, 2006; 52(6):68–70, 72, 74 passim.
14.
AbbruzzeseL, RizzoL, FanelliG, et al.Effectiveness and safety of a novel gel dressing in the management of neuropathic leg ulcers in diabetic patients: A prospective double-blind randomized trial. Int J Low Extrem Wounds, 2009; 8(3):134–140; doi: 10.1177/1534734609344140
15.
BlumeP, DriverVR, TallisAJ, et al.Formulated collagen gel accelerates healing rate immediately after application in patients with diabetic neuropathic foot ulcers. Wound Repair Regen, 2011; 19(3):302–308; doi: 10.1111/j.1524-475x.2011.00669.x
16.
ShawJ, HughesCM, LaganKM, et al.The effect of topical phenytoin on healing in diabetic foot ulcers: a randomized controlled trial. Diabet Med, 2011; 28(10):1154–1157; doi: 10.1111/j.1464-5491.2011.03309.x
17.
GottrupF, CullenBM, KarlsmarkT, et al.Randomized controlled trial on collagen/oxidized regenerated cellulose/silver treatment. Wound Repair Regen, 2013; 21(2):216–225; doi: 10.1111/wrr.12020
18.
KamaratosAV, TzirogiannisKN, IraklianouSA, et al.Manuka honey-impregnated dressings in the treatment of neuropathic diabetic foot ulcers. Int Wound J, 2014; 11(3):259–263; doi: 10.1111/j.1742-481X.2012.01082.x
19.
LeeM, HanSH, ChoiWJ, et al.Hyaluronic acid dressing (Healoderm) in the treatment of diabetic foot ulcer: A prospective, randomized, placebo-controlled, single-center study. Wound Repair Regen, 2016; 24(3):581–588; doi: 10.1111/wrr.12428
20.
TsangKK, KwongEW, ToTS, et al.A pilot randomized, controlled study of nanocrystalline silver, manuka honey, and conventional dressing in healing diabetic foot ulcer. Evid Based Complement Alternat Med, 2017; 2017:5294890; doi: 10.1155/2017/5294890
21.
GameF, JeffcoateW, TarnowL, et al.LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: An observer-masked, randomised controlled trial. Lancet Diabetes Endocrinol, 2018; 6(11):870–878; doi: 10.1016/s2213-8587(18)30240-7
22.
ParkKH, KwonJB, ParkJH, et al.Collagen dressing in the treatment of diabetic foot ulcer: A prospective, randomized, placebo-controlled, single-center study. Diabetes Res Clin Pract, 2019; 156:107861; doi: 10.1016/j.diabres.2019.107861
23.
ChandlerLA, AlvarezOM, BlumePA, et al.Wound conforming matrix containing purified homogenate of dermal collagen promotes healing of diabetic neuropathic foot ulcers: Comparative analysis versus standard of care. Adv Wound Care (New Rochelle), 2020; 9(2):61–67; doi: 10.1089/wound.2019.1024
24.
EssaMS, AhmadKS, ZayedME, et al.Comparative study between silver nanoparticles dressing (SilvrSTAT gel) and conventional dressing in diabetic foot ulcer healing: A prospective randomized study. Int J Low Extrem Wounds, 2023; 22(1):48–55; doi: 10.1177/1534734620988217
25.
HuangY-Y, LinC-W, ChengN-C, et al.Effect of a novel macrophage-regulating drug on wound healing in patients with diabetic foot ulcers. JAMA Netw Open, 2021; 4(9):e2122607; doi: 10.1001/jamanetworkopen.2021.22607
26.
ArmstrongDG, OrgillDP, GalianoRD, et al.A multi-centre, single-blinded randomised controlled clinical trial evaluating the effect of resorbable glass fibre matrix in the treatment of diabetic foot ulcers. Int Wound J, 2022; 19(4):791–801; doi: 10.1111/iwj
27.
LandsmanA, RoukisTS, DeFronzoDJ, et al.Living cells or collagen matrix: which is more beneficial in the treatment of diabetic foot ulcers?. Wounds, 2008; 20(5):111–116.
28.
ReyzelmanA, CrewsRT, MooreJC, et al.Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: A prospective, randomised, multicentre study. Int Wound J, 2009; 6(3):196–208; doi: 10.1111/j.1742-481x.2009.00585.x
29.
DriverVR, LaveryLA, ReyzelmanAM, et al.A clinical trial of Integra Template for diabetic foot ulcer treatment. Wound Repair Regen, 2015; 23(6):891–900; doi: 10.1111/wrr.12357
30.
ZelenCM, OrgillDP, SerenaTE, et al.An aseptically processed, acellular, reticular, allogenic human dermis improves healing in diabetic foot ulcers: A prospective, randomised, controlled, multicentre follow-up trial. Int Wound J, 2018; 15(5):731–739; doi: 10.1111/iwj.12920
31.
LantisJC, SnyderR, ReyzelmanAM, et al.Fetal bovine acellular dermal matrix for the closure of diabetic foot ulcers: A prospective randomised controlled trial. J Wound Care, 2021; 30(Suppl 7):S18–S27; doi: 10.1296/8/jowc.2021.30.Sup7.S18
32.
LulloveEJ, LidenB, WintersC, et al.A multicenter, blinded, randomized controlled clinical trial evaluating the effect of omega-3-rich fish skin in the treatment of chronic, nonresponsive diabetic foot ulcers. Wounds, 2021; 33(7):169–177; doi: 10.2527/0/wnds/2021.169177
33.
ArmstrongDG, OrgillDP, GalianoRD, et al.Use of a purified reconstituted bilayer matrix in the management of chronic diabetic foot ulcers improves patient outcomes vs standard of care: Results of a prospective randomised controlled multi-centre clinical trial. Int Wound J, 2022; 19(5):1197–1209; doi: 10.1111/iwj.13715
34.
LaveryLA, FulmerJ, ShebetkaKA, et al.The efficacy and safety of Grafix(®) for the treatment of chronic diabetic foot ulcers: Results of a multi-centre, controlled, randomised, blinded, clinical trial. Int Wound J, 2014; 11(5):554–560; doi: 10.1111/iwj.12329
35.
ZelenCM, SerenaTE, GouldL, et al.Treatment of chronic diabetic lower extremity ulcers with advanced therapies: A prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. Int Wound J, 2016; 13(2):272–282; doi: 10.1111/iwj.12566
36.
TettelbachW, CazzellS, ReyzelmanAM, et al.A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of diabetic foot ulcers: A prospective, multicentre, randomised, controlled study of 110 patients from 14 wound clinics. Int Wound J, 2019; 16(1):19–29; doi: 10.1111/iwj.12976
37.
TettelbachW, CazzellS, SigalF, et al.A multicentre prospective randomised controlled comparative parallel study of dehydrated human umbilical cord (EpiCord) allograft for the treatment of diabetic foot ulcers. Int Wound J, 2019; 16(1):122–130; doi: 10.1111/iwj.13001
38.
SerenaTE, YaakovR, MooreS, et al.A randomized controlled clinical trial of a hypothermically stored amniotic membrane for use in diabetic foot ulcers. J Comp Eff Res, 2020; 9(1):23–34.
39.
VevesA, FalangaV, ArmstrongDG, et al.Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: A prospective randomized multicenter clinical trial. Diabetes Care, 2001; 24(2):290–295; doi: 10.2337/diacare.24.2.290
40.
HanftJR, SurprenantMS. Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis. J Foot Ankle Surg, 2002; 41(5):291–299; doi: 10.1016/s1067-2516(02)80047-3
41.
MarstonWA, HanftJ, NorwoodP, et al.The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: Results of a prospective randomized trial. Diabetes Care, 2003; 26(6):1701–1705; doi: 10.2337/diacare.26.6.1701
42.
EdmondsM. Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds, 2009; 8(1):11–18; doi: 10.1177/1534734609331597
43.
UccioliL, GiuratoL, RuotoloV, et al.Two-step autologous grafting using HYAFF scaffolds in treating difficult diabetic foot ulcers: Results of a multicenter, randomized controlled clinical trial with long-term follow-up. Int J Low Extrem Wounds, 2011; 10(2):80–85; doi: 10.1177/1534734611409371
44.
YouHJ, HanSK, LeeJW, et al.Treatment of diabetic foot ulcers using cultured allogeneic keratinocytes—A pilot study. Wound Repair Regen, 2012; 20(4):491–499; doi: 10.1111/j.1524-475X.2012.00809.x
45.
YouHJ, HanSK, RhieJW. Randomised controlled clinical trial for autologous fibroblast-hyaluronic acid complex in treating diabetic foot ulcers. J Wound Care, 2014; 23(11):521–522, 524, 526–530; doi: 10.1296/8/jowc.2014.23.11.521
46.
MoonKC, SuhHS, KimKB, et al.Potential of allogeneic adipose-derived stem cell-hydrogel complex for treating diabetic foot ulcers. Diabetes, 2019; 68(4):837–846; doi: 10.2337/db18-0699
47.
ArmstrongDG, GalianoRD, OrgillDP, et al.Multi-centre prospective randomised controlled clinical trial to evaluate a bioactive split thickness skin allograft vs standard of care in the treatment of diabetic foot ulcers. Int Wound J, 2022; 19(4):932–944; doi: 10.1111/iwj.13759
48.
ArmstrongDG, OrgillDP, GalianoR, et al.A multicentre, randomised controlled clinical trial evaluating the effects of a novel autologous, heterogeneous skin construct in the treatment of Wagner one diabetic foot ulcers: Interim analysis. Int Wound J, 2022; 19(1):64–75; doi: 10.1111/iwj.13598
49.
LoeffelbeinDJ, RohlederNH, EddicksM, et al.Evaluation of human amniotic membrane as a wound dressing for split-thickness skin-graft donor sites. Biomed Res Int, 2014; 2014:572183; doi: 10.1155/2014/572183
50.
ThompsonP, HansonDS, LangemoD, et al.Comparing human amniotic allograft and standard wound care when using total contact casting in the treatment of patients with diabetic foot ulcers. Adv Skin Wound Care, 2019; 32(6):272–277; doi: 10.1097/01.Asw.0000557831.78645.85
51.
KoobTJ, LimJJ, MasseeM, et al.Properties of dehydrated human amnion/chorion composite grafts: Implications for wound repair and soft tissue regeneration. J Biomed Mater Res B Appl Biomater, 2014; 102(6):1353–1362; doi: 10.1002/jbm.b.33141
52.
LakmalK, BasnayakeO, HettiarachchiD. Systematic review on the rational use of amniotic membrane allografts in diabetic foot ulcer treatment. BMC Surg, 2021; 21(1):87; doi: 10.1186/s12893-021-01084-8
Davison-KotlerE, SharmaV, KangNV, et al.A universal classification system of skin substitutes inspired by factorial design. Tissue Eng Part B Rev, 2018; 24(4):279–288; doi: 10.1089/ten.TEB.2017.0477
55.
AalaaM, MehrdadN, BigdeliS, et al.Challenges and expectations of diabetic foot care from the patients' point of views. J Diabetes Metab Disord, 2021; 20(2):1111–1118; doi: 10.1007/s40200-021-00825-z
ShettyR, GiridharBS, PotphodeA. Role of ultrathin skin graft in early healing of diabetic foot ulcers: A randomized controlled trial in comparison with conventional methods. Wounds, 2022; 33(2):57–67; doi: 10.2527/0/wnds/2022.5767
KumarP. Classification of skin substitutes. Burns, 2008; 34(1):148–149; doi: 10.1016/j.burns.2007.04.016
60.
Ontario Health (Quality). Skin substitutes for adults with diabetic foot ulcers and venous leg ulcers: A health technology assessment. Ont Health Technol Assess Ser, 2021; 21(7):1–165.
61.
SamsellB, McLeanJ, CazzellS, et al.Health economics for treatment of diabetic foot ulcers: a cost-effectiveness analysis of eight skin substitutes. J Wound Care, 2019; 28(Suppl 9):S14–S26; doi: 10.1296/8/jowc.2019.28.Sup9.S14
62.
SchmiedovaI, DembickajaA, KiselakovaL, et al.Using of amniotic membrane derivatives for the treatment of chronic wounds. Membranes, 2021; 11(12):941; doi: 10.3390/membranes11120941
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
